Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2021

View Archived Issues

UBE-1099: a novel Keap1-Nrf2 PPI inhibitor for kidney disease

SUVN-4404091 shows efficacy in rat model of amphetamine-induced hyperlocomotion

New NMDA receptor antagonists described by Suzhou Nhwa Biomedical Technology

PharmaBlock Sciences discovers p300 and CREBBP inhibitors

SyneuRx International patents DAAO and/or 3C-like proteinase inhibitors

New GnRH-R antagonists identified at Shanghai Innofortune Biotech

XuanZhu Pharma divulges new DNA-dependent protein kinase inhibitors

Researchers develop CFTR-mutated cystic fibrosis murine model to allow gene-editing strategies

TQS-168 extends survival in mouse model of ALS

Trivalent PROTAC SIM-1 shows enhanced BET degradation and cytotoxicity

MEF2 as key regulator and potential therapeutic target for neurodegeneration

Omega Therapeutics offers pipeline and research update

9 Meters Biopharma and Gustave Roussy collaborate further on gut microbiome modulator NM-102

Monte Rosa selects MRT-2359 as first development candidate

Zika-specific therapy found to protect fetal mouse brains

Virpax announces contracts to support development and manufacturing of Envelta

Gain reports preclinical data on GT-02287 and GT-02329 for Gaucher's and GBA1 Parkinson's disease

Lennham discloses deuterated testosterone compound

BACH1 targeting has neuroprotective effects in Parkinson's disease

Biomea Fusion advances BMF-219 for leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...